Pfizer (PFE) Cash from Operations (2009 - 2026)

Pfizer has disclosed Cash from Operations across 18 years of filings, most recently posting 2615000000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 11.99% year-over-year to 2615000000.0; the TTM figure through Mar 2026 stood at 11984000000.0 (up 56.31% YoY), while the FY2025 annual figure was 11704000000.0, down 8.16% from the prior year.
• Cash from Operations slipped to 2615000000.0 in Q1 2026, from 5348000000.0 in the prior quarter.
• Over the last five years, Cash from Operations for PFE reached as high as 20685000000.0 in Q4 2022 and fell as low as 1781000000.0 in Q2 2024.
• The 5-year median for Cash from Operations is 3456000000.0 (2023), against an average of 4249800000.0.
• Annual changes were most pronounced in 2023 — Cash from Operations sank 114.79% — and 2025, when it surged 114.22%.
• A 5-year view of Cash from Operations shows it stood at 20685000000.0 in 2022, then slumped by 74.67% to 5240000000.0 in 2023, then rose by 14.94% to 6023000000.0 in 2024, then decreased by 11.21% to 5348000000.0 in 2025, then sank by 51.1% to 2615000000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 2615000000.0, 5348000000.0, and 4603000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.